RecruitingNot ApplicableNCT07464808
Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management
Sponsor
Ain Shams University
Enrollment
25 participants
Start Date
Nov 28, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients
Eligibility
Min Age: 21 Years
Inclusion Criteria4
- Adults (≥21 years) admitted to the burn unit with thermal burns ≥20% TBSA and < 60%.
- Admission to BICU within 48 hours of burn injury.
- Indication for VTE prophylaxis (e.g., immobilized, surgical intervention).
- Ability to provide informed consent
Exclusion Criteria4
- Pre-existing coagulopathy or anticoagulant therapy prior to injury.
- Patients with severe comorbidities (e.g., end-stage renal failure, advanced malignancy, hepatic disease).
- Need for therapeutic anticoagulant therapy.
- patients with extremes of weight, (45kg >=weight >= 150kg).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERfollow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay
follow up vte incidence and routine clexan dose modification
OTHERfollow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay
follow up of vte incidence with no routine dose modification unless indicated
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07464808